Skip to main content
162 search results for:

Hormone-receptor positive breast cancer 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 10-09-2022 | ESMO 2022 | Conference coverage | Article

    DAWNA-2 supports first-line dalpiciclib combo for advanced hormone receptor-positive breast cancer

    Dalpiciclib given in combination with an aromatase inhibitor offers a novel first-line treatment option for patients with locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer, say the DAWNA-2 investigators.

  2. 02-04-2019 | Advanced breast cancer | Editorial | Article

    The use of CDK4/6-inhibitors in advanced, hormone-receptor positive breast cancer: why, when and who?

    CDK4/6 inhibitors are a valuable addition to the treatment armamentarium for HR-positive, HER2-negative advanced breast cancer, but questions about their use remain. The research team behind the Dutch Sonia study explores some of the most pressing questions.

  3. 03-06-2018 | Advanced breast cancer | Article

    Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3

    Slamon DJ et al.  J Clin Oncol  2018; JCO2018789909. doi:10.1200/JCO.2018.78.9909

  4. 27-07-2018 | Advanced breast cancer | Article

    CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials

    Messina C et al. Breast Cancer Res Treat 2018; 172: 9. doi:10.1007/s10549-018-4901-0

  5. 20-11-2018 | Advanced breast cancer | Article

    Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial

    van Ommen-Nijhof A et al.  BMC Cancer 2018; 18:1146. doi:10.1186/s12885-018-4978-1

  6. 14-12-2017 | HER2-targeted agents | Article

    Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE

    Johnston SRD et al.  J Clin Oncol  2018; 36(8): 741-748. doi:10.1200/JCO.2017.74.7824

  7. 05-06-2023 | Breast cancer | Conference coverage | Article
    ASCO 2023

    Adjuvant ribociclib reduces recurrence risk in early breast cancer

    Supplementing endocrine therapy with ribociclib significantly decreases the relapse risk in people with hormone receptor-positive, HER2-negative, early breast cancer.

  8. 01-03-2023 | Breast cancer | News | Article

    PRIME II ‘extremely reassuring’ on radiotherapy omission in older women with early breast cancer

    The 10-year data from the PRIME II trial suggest that radiotherapy after breast-conserving surgery can be omitted for women aged 65 years or older with low-risk, hormone receptor-positive early breast cancer.

  9. 12-12-2022 | SABCS 2022 | Conference coverage | Article

    Phase 3 data support add-on capivasertib in people with AI-resistant advanced breast cancer

    The addition of the AKT inhibitor capivasertib to fulvestrant significantly prolongs the progression-free survival of people with hormone receptor-positive, HER2-negative advanced breast cancer that is resistant aromatase inhibitors, indicate the results of CAPItello-291.

  10. 08-12-2022 | SABCS 2022 | Conference coverage | Article

    monarchE 4-year results show abemaciclib benefit is maintained beyond treatment completion

    The 4-year results from monarchE indicate that the invasive disease-free survival gain offered by adjuvant abemaciclib in people with high-risk, hormone receptor-positive, HER2-negative, early breast cancer is maintained even after the 2-year treatment period.

  11. 09-12-2022 | SABCS 2022 | Conference coverage | Article

    Encouraging data for neoadjuvant T-DXd in HER2-low early breast cancer

    Trastuzumab deruxtecan has demonstrated promising efficacy and tolerability in the neoadjuvant treatment of HER2-low, hormone receptor-positive early breast cancer in the TRIO-US B-12 TALENT trial.

  12. 08-12-2022 | SABCS 2022 | Conference coverage | Article

    First-line ribociclib plus ET RIGHT Choice for aggressive advanced breast cancer

    Ribociclib plus endocrine therapy is associated with a significant progression-free survival benefit relative to combination chemotherapy in treatment-naïve patients with hormone receptor-positive, HER2-negative, advanced breast cancer with aggressive features, suggest trial data.

  13. 21-09-2022 | ESMO 2022 | Conference coverage | Article

    Extended anastrozole benefits dependent on tumor characteristics

    Extending adjuvant aromatase inhibition to beyond 5 years of sequential therapy should not be recommended to all postmenopausal women with hormone receptor-positive early breast cancer, but some subgroups may benefit, research suggests.

  14. play
    12-09-2022 | ESMO 2022 | Conference coverage | Video

    TROPiCS-02 shows sacituzumab govitecan OS benefit in HR+, HER2– advanced breast cancer

    Hope Rugo outlines the latest results from the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor-positive, HER2-negative advanced breast cancer and discusses where the antibody–drug conjugate fits into the treatment paradigm.

  15. 09-09-2022 | ESMO 2022 | Conference coverage | Article

    Sacituzumab govitecan boosts HR+, HER2– advanced breast cancer OS

    Among people with endocrine-resistant, hormone receptor-positive, HER2-negative advanced breast cancer, sacituzumab govitecan is associated with significantly improved overall survival relative to standard of care, show data from TROPiCS-02.

  16. 10-09-2022 | ESMO 2022 | Conference coverage | Article

    MONARCH 3: OS ‘numerically favors’ abemaciclib combination therapy

    Updated findings from the MONARCH 3 trial show a nonsignificant overall survival gain with the addition of abemaciclib to a first-line nonsteroidal aromatase inhibitor in postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer.

  17. 18-11-2022 | Breast cancer | News | Article

    Novel nonhormonal agent shows promise for hot flashes, night sweats in patients with breast cancer

    The oral nonhormonal agent Q-122 appears to be an efficacious and well tolerated option for the control of vasomotor symptoms in women with breast cancer receiving adjuvant endocrine therapy, suggest phase 2 trial data.

  18. 25-11-2022 | Breast cancer | News | Article

    GIM2 defines ‘optimal’ high-risk early breast cancer adjuvant chemotherapy

    End-of-study findings from the GIM2 trial indicate that adjuvant anthracyclines plus taxane chemotherapy for high-risk early breast cancer should be given in a dose-dense regimen and should not include fluorouracil.

  19. 25-07-2022 | Breast cancer | News | Article

    Postmenopausal hormone therapy may be feasible for early-stage breast cancer survivors

    Postmenopausal women who use vaginal estrogen therapy or menopausal hormone therapy after surgery for early-stage, estrogen receptor-positive breast cancer may not have an increased risk for recurrence or death, suggest Danish investigators.

  20. 10-10-2022 | Breast cancer | News | Article

    Lower pCR rate highlighted for male breast cancer after neoadjuvant chemotherapy

    Men are less likely than women to achieve a pathologic complete response to neoadjuvant chemotherapy for invasive, nonmetastatic breast cancer, US researchers report.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.